1. Kane, J, Honigfeld, G, Singer, J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
Google Scholar | Crossref | Medline2. Demjaha, A, Lappin, JM, Stahl, D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 2017; 47: 1981–1989.
Google Scholar | Crossref | Medline3. Lehman, AF, Lieberman, JA, Dixon, LB, et al.; American Psychiatric Association and Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(Suppl. 2): 1–56.
Google Scholar | Medline | ISI4. Taylor, DM. Clozapine for treatment-resistant schizophrenia: still the gold standard? CNS Drugs 2017; 31: 177–180.
Google Scholar | Crossref | Medline5. Idänpään-Heikkilä, J, Alhava, E, Olkinuora, M, et al. Letter: clozapine and agranulocytosis. Lancet 1975; 2: 611.
Google Scholar | Crossref | Medline | ISI6. Shah, P, Iwata, Y, Plitman, E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res 2018; 268: 114–122.
Google Scholar | Crossref | Medline7. Nielsen, J, Dahm, M, Lublin, H, et al. Psychiatrists attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24: 965–971.
Google Scholar | SAGE Journals | ISI8. Gee, S, Vergunst, F, Howes, O, et al. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014; 130: 16–24.
Google Scholar | Crossref | Medline9. Daod, E, Krivoy, A, Shoval, G, et al. Psychiatrists’ attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey. Psychiatry Res 2019; 275: 155–161.
Google Scholar | Crossref | Medline10. Okhuijsen-Pfeifer, C, Cohen, D, Bogers, JPAM, et al. Differences between physicians’ and nurse practitioners’ viewpoints on reasons for clozapine underprescription. Brain Behav 2019; 9: e01318.
Google Scholar | Crossref | Medline11. Verdoux, H, Quiles, C, Bachmann, CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res 2018; 201: 10–19.
Google Scholar | Crossref | Medline12. Apiquian, R, Fresán, A, de, la, Fuente-Sandoval, C, et al. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004; 4: 12.
Google Scholar | Crossref | Medline13. de Hert, M, de Beugher, A, Sweers, K, et al. Knowledge of psychiatric nurses about the potentially lethal side-effects of clozapine. Arch Psychiatr Nurs 2016; 30: 79–83.
Google Scholar | Crossref | Medline14. Grover, S, Balachander, S, Chakarabarti, S, et al. Prescription practices and attitude of psychiatrists towards clozapine: a survey of psychiatrists from India. Asian J Psychiatr 2015; 18: 57–65.
Google Scholar | Crossref | Medline15. Marinkovic, D, Timotijevic, I, Babinski, T, et al. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 537–544.
Google Scholar | Crossref | Medline | ISI16. Ignjatović Ristić, D, Cohen, D, Obradović, A, et al. The glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord J Psychiatry 2018; 72: 124–129.
Google Scholar | Crossref | Medline17. Institute of Public Health of Serbia “Dr Milan Jovanovic Batut . Health statistical yearbook of republic of Serbia 2018, http://www.batut.org.rs/index.php?content=77 (accessed 10 April 2021).
Google Scholar18. Statistical Office of the Republic of Serbia . 2018 demographic yearbook, https://publikacije.stat.gov.rs/G2019/Pdf/G201914016.pdf (accessed 10 April 2021).
Google Scholar19. Moreno-Küstner, B, Martín, C, Pastor, L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One 2018; 13: e0195687.
Google Scholar | Crossref | Medline20. Institute of Public Health of Serbia “Dr Milan Jovanovic Batut . Health statistical yearbook of Republic of Serbia 2013, http://www.batut.org.rs/index.php?content=77 (accessed 10 April 2021).
Google Scholar21. Medicines and Medical Devices Agency of Serbia . Trade and consumption of medicines for human use in the republic of Serbia in 2018, https://www.alims.gov.rs/ciril/files/2020/08/PPL-2018.pdf (accessed 10 April 2021).
Google Scholar22. Latas, M, Stojkovic, T, Ralic, T, et al. Psychiatrists’ psychotropic drug prescription preferences for themselves or their family members. Psychiatr Danub 2012; 24: 182–187.
Google Scholar | Medline23. Kelly, DL, Ben-Yoav, H, Payne, GF, et al. Blood draw barriers for treatment with clozapine and development of a point-of-care monitoring device. Clin Schizophr Relat Psychoses 2018; 12: 23–30.
Google Scholar | Crossref | Medline24. Geers, LM, Cohen, D, Wehkamp, LM, et al. Dried blood spot analysis for therapeutic drug monitoring of clozapine. J Clin Psychiatry 2017; 78: e1211–e1218.
Google Scholar | Crossref | Medline25. Buckley, P, Miller, A, Olsen, J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27: 615–628.
Google Scholar | Crossref | Medline | ISI26. Chong, SA, Remington, G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26: 421–440.
Google Scholar | Crossref | Medline | ISI27. Veerman, SR, Schulte, PF, Begemann, MJ, et al. Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry 2014; 47: 185–194.
Google Scholar | Crossref | Medline28. Rajkumar, AP, Poonkuzhali, B, Kuruvilla, A, et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50–56.
Google Scholar | Crossref | Medline | ISI29. McCutcheon, R, Beck, K, D’Ambrosio, E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018; 137: 39–46.
Google Scholar | Crossref | Medline30. Tang, Y, Horvitz-Lennon, M, Gellad, WF, et al. Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large medicaid program. Psychiatr Serv 2017; 68: 579–586.
Google Scholar | Crossref | Medline31. Falzer, PR, Garman, DM. Optimizing clozapine through clinical decision making. Acta Psychiatr Scand 2012; 126: 47–58.
Google Scholar | Crossref | Medline32. Tungaraza, TE, Farooq, S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015; 5: 88–96.
Google Scholar | SAGE Journals | ISI33. Cohen, D. Clozapine and gastrointestinal hypomotility. CNS Drugs 2017; 31: 1083–1091.
Google Scholar | Crossref | Medline34. Cohen, D, Bogers, JP, van Dijk, D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307–1312.
Google Scholar | Crossref | Medline | ISI35. Ignjatović Ristic, D, Cohen, D, Hinic, D, et al. Subjective well-being under clozapine measured with the Serbian version of GASS-C: preliminary results. Eur Psychiatry 2017; 41: s815.
Google Scholar | Crossref36. Legge, SE, Hamshere, M, Hayes, RD, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 2016; 174: 113–119.
Google Scholar | Crossref | Medline37. Nielsen, J, Correll, CU, Manu, P, et al. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? J Clin Psychiatry 2013; 74: 603–613.
Google Scholar | Crossref | Medline | ISI38. Taylor, D, Shapland, L, Laverick, G, et al. Clozapine–a survey of patient perceptions. Psychiatric Bulletin 2000; 24: 450–452.
Google Scholar | Crossref39. Wirshing, DA, Wirshing, WC, Kysar, L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–363.
Google Scholar | Crossref | Medline | ISI40. Henderson, DC, Cagliero, E, Gray, C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–981.
Google Scholar | Crossref | Medline | ISI41. Taipale, H, Tanskanen, A, Mehtälä, J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61–68.
Google Scholar | Crossref | Medline42. Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620–627.
Google Scholar | Crossref | Medline | ISI43. Leucht, S. Psychiatric treatment guidelines: doctors’ non-compliance or insufficient evidence? Acta Psychiatr Scand 2007; 115: 417–419.
Google Scholar | Crossref | Medline44. Weinmann, S, Koesters, M, Becker, T. Effects of implementation of psychiatric guidelines on provider performance and patient outcome: systematic review. Acta Psychiatr Scand 2007; 115: 420–433.
Google Scholar | Crossref | Medline45. Cohen, D. Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand 2014; 130: 154–155.
Google Scholar | Crossref | Medline | ISI46. Atkin, K, Kendall, F, Gould, D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483–488.
Google Scholar | Crossref | Medline | ISI47. Myles, N, Myles, H, Xia, S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 2018; 138: 101–109.
Google Scholar | Crossref | Medline48. Cohen, D, Farooq, S. Mandatory certification for clozapine prescribing. Eur Psychiatry 2020; 64: e12.
Google Scholar | Crossref | Medline49. Bogers, JP, Bui, H, Herruer, M, et al. Capillary compared to venous blood sampling in clozapine treatment: patients’ and healthcare practitioners’ experiences with a point-of-care device. Eur Neuropsychopharmacol 2015; 25: 319–324.
Google Scholar | Crossref | Medline | ISI50. Bogers, JP, Schulte, PF, Van Dijk, D, et al. Clozapine underutilization in the treatment of Schizophrenia: how can clozapine prescription rates be improved? J Clin Psychopharmacol 2016; 36: 109–111.